Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginesatide for Anemia in Hemodialysis Patients (AFX01-15)
NCT00680043Phase 2Completed
- Sponsor
- Affymax, Inc.
- Start
- Jun 2008
- Primary completion
- Aug 2009
- Modality
- Peptides, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginesatide in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Affymax, Inc. Primary endpoint: Mean Change in Hemoglobin Between Baseline and the Evaluation Period at 28 weeks. Started Jun 2008; status: completed.
02
Drugs
peginesatide
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00680043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00680043.